{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:02:04Z","timestamp":1789884124179,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdsjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jdermsci.2015.10.009","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T20:56:39Z","timestamp":1445892999000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study"],"prefix":"10.1016","volume":"81","author":[{"given":"Hidemi","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ootaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2015.10.009_bib0005","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T Cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0015","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.4049\/jimmunol.180.11.7423","article-title":"Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes","volume":"180","author":"P\u00e8ne","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0020","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0025","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.4049\/jimmunol.181.6.4299","article-title":"Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities","volume":"181","author":"Rickel","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0030","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0040","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Van","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2014.05.007","article-title":"Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study","volume":"75","author":"Osamu","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jdermsci.2015.10.009_bib0065","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.11465","article-title":"Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3763 patients with rheumatoid arthritis","volume":"49","author":"Matsuda","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36)","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0080","first-page":"1583","article-title":"Development of the Japanese version of the Psoriasis Disability Index (PDI), the Psoriasis Specific QOL Index: results of the validation study","volume":"116","author":"Osamu","year":"2006","journal-title":"Jpn. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0085","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2133.2007.07817.x","article-title":"The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis","volume":"156","author":"Katugampola","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"Suppl. 2","key":"10.1016\/j.jdermsci.2015.10.009_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2015.10.009_bib0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1346-8138.2011.01459.x","article-title":"Japanese infliximab study investigators. dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab","volume":"39","author":"Torii","year":"2012","journal-title":"J. Dermatol."},{"issue":"January 1","key":"10.1016\/j.jdermsci.2015.10.009_bib0100","doi-asserted-by":"crossref","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota","year":"2015","journal-title":"BMJ Open"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318111530061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318111530061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T07:50:51Z","timestamp":1537257051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092318111530061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S092318111530061X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2015.10.009","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2015.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}